Evidence map›Paper›PMID 36160146›Full record

ArticleFrontiers in medicine2022

Proposal for standardizing normal insulin ranges in Brazilian patients and a new classification of metabolic syndrome.

Pedro Renato Chocair, Precil Diego Miranda de Menezes Neves, Victor Augusto Hamamoto Sato, Sara Mohrbacher, Érico Souza Oliveira, Leonardo Victor Barbosa Pereira, Alessandra Martins Bales, Fagner Pereira da Silva, John A Duley, Américo Lourenço Cuvello-Neto

Abstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Pedro Renato ChocairInternal Medicine and Nephrology Service, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
Precil Diego Miranda de Menezes NevesInternal Medicine and Nephrology Service, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
Victor Augusto Hamamoto SatoInternal Medicine and Nephrology Service, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
Sara MohrbacherInternal Medicine and Nephrology Service, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
Érico Souza OliveiraInternal Medicine and Nephrology Service, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
Leonardo Victor Barbosa PereiraInternal Medicine and Nephrology Service, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
Alessandra Martins BalesInternal Medicine and Nephrology Service, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
Fagner Pereira da SilvaNursing Department, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
John A DuleySchool of Pharmacy, The University of Queensland, Brisbane, QLD, Australia.
Américo Lourenço Cuvello-NetoInternal Medicine and Nephrology Service, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Insulin resistance and/or hyperinsulinemia are closely linked to adiposity, metabolic syndrome (MetS) and prolonged inflammatory processes. Methods: We retrospectively analyzed 1,018 adult individuals with a mean age of 46 years (74% male) and classified them as: Metabolically normal: without any of the five criteria of the International Diabetes Federation (IDF) used for the diagnosis of MetS, plus normal fasting insulin (Men < 8 mU/L, Women < 10 mU/L); Level 1 MetS: with one or two IDF criteria, plus hyperinsulinemia (Men: ≥ 8 mU/L), and Women: ≥ 10 mU/L); Level 2 MetS: with three or more IDF criteria, plus hyperinsulinemia. Results: The mean values for fasting insulinemia in metabolically normal individuals was 4.6 ± 1.8 mU/L and 5.6 ± 2.3 mU/L, while their means for the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) were 1.0 and 1.2 for men and women, respectively. In addition, the mean values for insulin (and HOMA-IR) for individuals with two normal anthropometric parameters (body mass index and waist girth), or two normal anthropometric parameters plus no IDF criteria, were similar to the metabolically normal group. Based on the obtained mean + 2 SD, we established the following insulin (and HOMA-IR) values as diagnostic cut-offs for hyperinsulinemia: Men: ≥ 8 mU/L (≥ 1.5), and Women: ≥ 10 mU/L (≥ 2.0). The mean serum insulin was significantly higher for individuals with Level 1 MetS (approx. 9 mU/L for both genders) compared with metabolically normal individuals, as was the prevalence of hepatic steatosis, which was more evident in men. Thus, the presence of one or two abnormal IDF criteria, combined with hyperinsulinemia and/or raised HOMA-IR, suggests the presence of MetS and insulin resistance. Patients of both genders with Level 2 MetS had higher serum insulin and/or HOMA-IR values than Level 1, as well as a higher prevalence of hypertension and hepatic steatosis, being more pronounced among men. The process was progressive and proportional to the degree of hyperinsulinemia. Conclusion: It is proposed that intervention against MetS progression should be started in individuals with Level 1 MetS, rather than waiting for more criteria for diagnostic confirmation, which this should help to reduce the occurrence of known complications such as type 2 diabetes, atherosclerosis, hypertension, and chronic kidney disease, among others.

Indexed as

diabetesHOMA-IRhyperinsulinemiainsulinmetabolic syndromeobesity

Identifiers

PMID36160146
PMCPMC9500149

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.